Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study

Inclusion Criteria:

- Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a
BRAF inhibitor

- Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC)
including an arm with an oral Akt inhibitor

- Able and willing to provide informed consent

Exclusion Criteria:

- Factors which in the investigator's opinion would prevent the participant from
completing the protocol, including poor compliance during previous studies or an
unpredictable schedule

- Unable to give informed consent